期刊
NATURE REVIEWS DRUG DISCOVERY
卷 20, 期 3, 页码 200-216出版社
NATURE PORTFOLIO
DOI: 10.1038/s41573-020-00114-z
关键词
-
资金
- Austrian Science Fund (FWF)
- Australian Research Council DECRA Fellowship
- Ministerio de Ciencia, Innovacion y Universidades, Spain [AGL2017-89417-R]
- National Research Foundation (NRF) [019R1A2C1009231]
- MEST of Korea for Tumour Microenvironment Global Core Research Center (GCRC) [NRF-2011-0030001]
- Creative-Pioneering Researchers Program through Seoul National University [370C-20160062]
- Brain Korea 21 (BK21) PLUS programme
- `Recherche Cancer et Sang' foundation
- `Recherches Scientifiques Luxembourg' association
- `Een Haerz fir kriibskrank Kanner' association
- Action LIONS `Vaincre le Cancer' association
- Televie Luxembourg - Cancer Research UK [C20953/A18644]
- Biotechnology and Biological Sciences Research Council [BB/L01923X/1]
- Reata Pharmaceuticals
- Tenovus Scotland [T17/T14]
- BMBF [TUNGER 036/FUCOFOOD]
- AIF (AGEsense)
- European Union [739582, 664620, BG05M2OP001-1.003-001-C01]
- European Regional Development Fund through the ` Science and Education for Smart Growth' Operational Programme
- UK Medical Research Council [MC_UU_12011/4]
- National Institute for Health Research [NF-SI-0515-10042]
- (NIHR Southampton Biomedical Research Centre)
- European Union (Erasmus+ Capacity-Building ENeA SEA Project) [289346, 613977]
- US National Institute On Ageing of the National Institutes of Health [U24AG047867]
- UK ESRC
- BBSRC [ES/M00919X/1]
- Wilhelm Doerenkamp-Stiftung
- national funds through FCT-Foundation for Science and Technology of Portugal [UIDB/04423/2020, UIDP/04423/2020, HKBU SDF160603-P02]
- Ministerio de Economia y Competitividad, Spain [AGL2017-88083-R]
- Romanian Ministry of Research and Innovation, CNCS -UEFISCDI [PN-III-P11.1-PD-2016-1900]
- NIH [G12-MD007591]
- Kleberg Foundation [R01-AG066749]
- Swiss National Science Foundation (Schweizerischer Nationalfonds, SNF)
- Horizon 2020 programme of the European Union [691158]
- Austrian Science Fund [FWF: P24587, 2018]
- University of Vienna, Austria
- group of Cellular and Molecular Nutrition (BJ-Lab) at the Institute of Food Sciences, National Research Council
- Avellino, Italy [UIDB/00211/2020]
- FCT/MCTES through national funds [FWF S10711]
- National Centre for Research and Development [4/POLTUR-1/2016]
- National Science Centre [2017/27/B/NZ4/00917]
- Medical University of Lublin, Poland
- Universidad Central de Chile, through Direccion de Investigacion y Postgrado
- Austrian Research Promotion Agency (FFG)
- Instituto de Salud Carlos III, CIBEROBN [CB12/03/30038]
- EU-COST Action [CA16112]
- DFG, BMBF
- DAAD, AvH and Land Baden Wurttemberg
- Swiss National Science Foundation (SNF) [310030E-164289, 31003A_163424, 316030_164095]
- University of Vienna, Vienna, Austria
- EPSRC CASE Award [35/01.09.2016, 103375, PNCDI III 2015-2020, 29PFE/18.10.2018]
- Italian Ministry for University and Research (MIUR) [2017XYBP2R]
- Marie Curie Actions (MSCA) [691158] Funding Source: Marie Curie Actions (MSCA)
- Swiss National Science Foundation (SNF) [310030E-164289, 31003A_163424] Funding Source: Swiss National Science Foundation (SNF)
- National Research Foundation of Korea [2011-0030001] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Natural products and their analogues have historically played a significant role in pharmacotherapy, however, they also present challenges. Recent technological and scientific developments are addressing these challenges and revitalizing interest in natural products as drug leads, particularly for combating antimicrobial resistance.
Natural products and their structural analogues have historically made a major contribution to pharmacotherapy, especially for cancer and infectious diseases. Nevertheless, natural products also present challenges for drug discovery, such as technical barriers to screening, isolation, characterization and optimization, which contributed to a decline in their pursuit by the pharmaceutical industry from the 1990s onwards. In recent years, several technological and scientific developments - including improved analytical tools, genome mining and engineering strategies, and microbial culturing advances - are addressing such challenges and opening up new opportunities. Consequently, interest in natural products as drug leads is being revitalized, particularly for tackling antimicrobial resistance. Here, we summarize recent technological developments that are enabling natural product-based drug discovery, highlight selected applications and discuss key opportunities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
